Go Pro
→ Move your money (NOT into the next AI IPO) (From Stansberry Research) (Ad)tc pixel Free MBOT Stock Alerts

Microbot Medical (MBOT) Financials

Microbot Medical logo
$1.86 -0.01 (-0.53%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$1.87 +0.01 (+0.48%)
As of 07/9/2026 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Microbot Medical

Annual Income Statements for Microbot Medical

This table shows Microbot Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -0.92 9.66 -2.95 -7.26 -7.25 -9.17 -11 -13 -11 -11 -13
Consolidated Net Income / (Loss)		 0.91 -9.66 -2.95 -7.26 -7.25 -9.17 -11 -13 -11 -11 -13
Net Income / (Loss) Continuing Operations		 0.91 9.64 -2.95 -7.26 -7.25 -9.17 -11 -13 -11 -11 -13
Total Pre-Tax Income 		0.91 9.64 -2.95 -7.26 -7.25 -9.17 -11 -13 -11 -11 -13
Total Operating Income		 0.92 9.64 5.27 -7.24 -7.24 -9.09 -11 -13 -9.86 -12 -15
Total Gross Profit		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 -0.92 -9.64 5.27 7.24 7.24 9.09 11 13 9.86 12 15
Selling, General & Admin Expense		 -0.09 -8.73 -4.17 4.73 4.19 5.69 5.20 5.55 4.13 5.00 8.46
Research & Development Expense		 -0.82 -0.90 -1.10 2.52 3.05 3.40 6.15 7.74 5.72 6.63 6.28
Total Other Income / (Expense), net		 -0.01 0.00 2.32 -0.02 -0.01 -0.08 0.04 0.11 -0.88 0.18 1.60
Interest & Investment Income		 - - 2.32 -0.02 -0.10 -0.08 0.04 0.12 0.23 0.18 1.29
Other Income / (Expense), net		 - - - - 0.10 - 0.00 -0.01 -1.11 - 0.32
Basic Earnings per Share		 $0.04 $0.40 ($2.76) ($2.41) ($1.70) ($1.29) ($1.59) ($1.81) ($1.05) ($0.73) ($0.29)
Weighted Average Basic Shares Outstanding		 95.81M 14.29M 2.18M 2.90M 4.27M 7.12M 7.11M 7.26M 10.20M 15.64M 45.79M
Diluted Earnings per Share		 $0.04 $0.40 ($2.76) ($2.41) ($1.70) ($1.29) - ($1.81) ($1.05) ($0.73) ($0.29)
Weighted Average Diluted Shares Outstanding		 95.81M 14.29M 2.18M 2.90M 4.27M 7.12M 7.11M 7.26M 10.20M 15.64M 45.79M
Weighted Average Basic & Diluted Shares Outstanding		 95.81M 14.29M 2.18M 2.90M 4.27M 7.12M 7.11M 8.13M 14.40M 34.74M 67.16M

Quarterly Income Statements for Microbot Medical

This table shows Microbot Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.45 -3.15 -2.37 -2.47 -3.22 -3.39 -2.60 -3.50 -3.58 -3.46 -3.67
Consolidated Net Income / (Loss)		 -2.45 -3.15 -2.37 -2.47 -3.22 -3.39 -2.60 -3.50 -3.58 -3.46 -3.67
Net Income / (Loss) Continuing Operations		 -2.45 -3.15 -2.37 -2.47 -3.22 -3.39 -2.60 -3.50 -3.58 -3.46 -3.67
Total Pre-Tax Income 		-2.45 -3.15 -2.37 -2.47 -3.22 -3.39 -2.60 -3.50 -3.58 -3.46 -3.67
Total Operating Income		 -2.54 -2.07 -2.38 -2.51 -3.30 -3.43 -3.02 -3.72 -3.86 -4.14 -4.32
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.11
Operating Revenue		 - - - - - - 0.00 - - - 0.11
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.10
Operating Cost of Revenue		 - - - - - - 0.00 - - - 0.10
Total Operating Expenses		 2.54 2.07 2.38 2.51 3.30 3.43 3.02 3.72 3.86 4.14 4.32
Selling, General & Admin Expense		 0.93 0.94 1.22 1.09 1.24 1.45 1.56 1.61 2.69 2.60 3.03
Research & Development Expense		 1.61 1.13 1.17 1.42 2.06 1.98 1.46 2.11 1.17 1.54 1.29
Total Other Income / (Expense), net		 0.10 -1.08 0.01 0.05 0.09 0.04 0.42 0.22 0.28 0.67 0.65
Interest & Investment Income		 0.10 0.03 0.01 0.05 0.09 0.04 0.10 0.22 0.28 0.67 0.65
Other Income / (Expense), net		 - - 0.00 0.00 - - 0.32 0.00 0.00 - 0.00
Basic Earnings per Share		 ($0.21) ($0.23) ($0.17) ($0.17) ($0.20) ($0.19) ($0.08) ($0.10) ($0.07) ($0.04) ($0.05)
Weighted Average Basic Shares Outstanding		 11.71M 10.20M 14.06M 14.85M 16.47M 15.64M 31.09M 36.49M 48.10M 45.79M 67.16M
Diluted Earnings per Share		 ($0.21) ($0.23) ($0.17) ($0.17) ($0.20) ($0.19) ($0.08) ($0.10) ($0.07) ($0.04) ($0.05)
Weighted Average Diluted Shares Outstanding		 11.71M 10.20M 14.06M 14.85M 16.47M 15.64M 31.09M 36.49M 48.10M 45.79M 67.16M
Weighted Average Basic & Diluted Shares Outstanding		 - 14.40M 14.40M 16.50M 16.93M 34.74M 36.38M 45.55M 67.16M 67.16M 67.16M

Annual Cash Flow Statements for Microbot Medical

This table details how cash moves in and out of Microbot Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -0.35 2.27 7.63 -5.55 28 -13 -6.15 -11 -0.00 0.65 0.81
Net Cash From Operating Activities		 -0.77 -0.79 -4.86 -5.31 -6.45 -7.25 -9.35 -12 -8.53 -8.83 -13
Net Cash From Continuing Operating Activities		 -0.77 -0.79 -5.33 -5.31 -6.45 -7.25 -9.35 -12 -8.53 -8.83 -13
Net Income / (Loss) Continuing Operations		 -0.92 -9.66 -7.59 -7.26 -7.25 -9.17 -11 -13 -11 -11 -13
Consolidated Net Income / (Loss)		 -0.92 -9.66 -7.59 -7.26 -7.25 -9.17 -11 -13 -11 -11 -13
Depreciation Expense		 0.02 0.01 0.02 0.05 0.08 0.07 0.08 0.10 0.11 0.09 0.05
Non-Cash Adjustments To Reconcile Net Income		 0.01 8.01 2.80 1.47 0.98 1.87 1.39 1.75 2.11 1.58 1.06
Changes in Operating Assets and Liabilities, net		 0.13 0.86 -0.08 0.42 -0.27 -0.02 0.50 -0.23 -0.01 0.94 -1.01
Net Cash From Investing Activities		 -0.00 -0.03 -0.06 -0.22 -2.45 -2.77 3.20 -3.84 1.97 1.54 -72
Net Cash From Continuing Investing Activities		 -0.00 -0.03 -0.06 -0.22 -2.45 -2.77 3.20 -3.84 1.97 1.54 -72
Purchase of Property, Plant & Equipment		 -0.00 -0.03 -0.06 -0.22 -0.22 -0.09 -0.07 -0.08 -0.03 -0.03 -0.06
Purchase of Investments		 - - - 0.00 -2.50 -5.20 0.00 -3.75 -10 -5.12 -83
Sale and/or Maturity of Investments		 - - - - 0.00 2.52 0.27 0.00 12 6.68 11
Net Cash From Financing Activities		 0.41 3.08 13 -0.02 37 -3.38 0.00 4.32 6.56 7.94 86
Net Cash From Continuing Financing Activities		 0.41 3.08 13 -0.02 37 -3.38 0.00 4.32 6.56 7.94 86
Issuance of Common Equity		 - 0.00 13 0.00 37 - 0.00 4.32 6.56 7.94 86
Other Financing Activities, net		 0.00 2.33 0.32 - 0.00 -3.38 - - - 0.00 0.00

Quarterly Cash Flow Statements for Microbot Medical

This table details how cash moves in and out of Microbot Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -4.39 1.14 -1.31 1.30 -1.99 2.64 0.10 0.87 2.62 -2.79 -0.06
Net Cash From Operating Activities		 -1.66 -1.82 -2.42 -1.96 -2.76 -1.69 -2.87 -2.57 -3.84 -3.76 -5.05
Net Cash From Continuing Operating Activities		 -1.66 -1.82 -2.42 -1.96 -2.76 -1.69 -2.87 -2.57 -3.84 -3.76 -5.05
Net Income / (Loss) Continuing Operations		 -2.45 -3.15 -2.37 -2.47 -3.22 -3.39 -2.60 -3.50 -3.58 -3.46 -3.67
Consolidated Net Income / (Loss)		 -2.45 -3.15 -2.37 -2.47 -3.22 -3.39 -2.60 -3.50 -3.58 -3.46 -3.67
Depreciation Expense		 0.02 0.04 0.03 0.01 0.02 0.03 0.02 0.01 0.01 0.01 0.01
Non-Cash Adjustments To Reconcile Net Income		 0.27 1.12 0.69 0.33 0.28 0.28 0.26 0.12 0.17 0.52 0.00
Changes in Operating Assets and Liabilities, net		 0.51 0.18 -0.77 0.16 0.15 1.39 -0.54 0.80 -0.44 -0.82 -1.39
Net Cash From Investing Activities		 -2.57 2.96 -1.28 1.19 0.14 1.50 -25 -1.31 -45 -1.53 5.00
Net Cash From Continuing Investing Activities		 -2.57 2.96 -1.28 1.19 0.14 1.50 -25 -1.31 -45 -1.53 5.00
Purchase of Property, Plant & Equipment		 -0.03 0.01 -0.01 -0.00 - -0.01 -0.01 -0.01 -0.01 -0.03 -0.11
Purchase of Investments		 -5.19 -1.68 -5.12 - - - -28 -3.80 -48 -3.01 -1.25
Sale and/or Maturity of Investments		 2.64 4.64 3.85 1.19 0.14 1.50 3.30 2.50 3.30 1.50 6.50
Other Investing Activities, net		 - - - - - - 0.00 - - - -0.15
Net Cash From Financing Activities		 -0.16 - 2.40 2.07 0.63 2.83 28 4.75 51 2.51 0.00
Net Cash From Continuing Financing Activities		 -0.16 - 2.40 2.07 0.63 2.83 28 4.75 51 2.51 0.00
Issuance of Common Equity		 -0.16 - 2.40 2.07 0.63 2.83 28 4.75 51 2.51 0.00

Annual Balance Sheets for Microbot Medical

This table presents Microbot Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 0.53 3.37 11 6.09 37 26 17 9.54 8.33 6.03 82
Total Current Assets		 0.49 3.32 11 5.83 36 25 16 8.81 7.92 5.82 80
Cash & Equivalents		 0.44 2.71 11 5.24 29 20 13 2.44 2.47 3.11 3.91
Restricted Cash		 - 0.00 0.03 0.03 4.36 0.08 0.09 0.08 0.05 0.05 0.00
Short-Term Investments		 - - - 0.00 2.52 5.00 2.00 5.76 3.92 2.36 75
Accounts Receivable		 0.05 - - - - - - - - - 0.00
Inventories, net		 - - - - - - - - - 0.00 0.58
Prepaid Expenses		 - - - 0.57 0.29 0.52 0.30 0.53 0.15 0.30 0.64
Other Current Assets		 - 0.61 0.12 - - - 0.00 0.00 1.34 - 0.00
Plant, Property, & Equipment, net		 0.04 0.05 0.09 0.26 0.23 0.25 0.24 0.22 0.15 0.08 0.09
Total Noncurrent Assets		 0.00 0.00 0.00 0.00 0.96 0.78 0.64 0.50 0.26 0.13 1.63
Other Noncurrent Operating Assets		 - - - 0.00 0.96 0.78 0.64 0.50 0.26 0.13 1.57
Other Noncurrent Nonoperating Assets		 - - - - - - - - - 0.00 0.06
Total Liabilities & Shareholders' Equity		 0.53 3.37 11 6.09 37 26 17 9.54 8.33 6.03 82
Total Liabilities		 0.42 1.17 0.56 4.76 5.59 1.97 2.39 2.25 3.83 2.50 3.99
Total Current Liabilities		 0.17 0.78 0.53 4.76 4.83 1.35 1.98 2.07 3.79 2.46 3.42
Accounts Payable		 0.03 0.51 0.08 0.63 0.28 0.28 0.28 0.12 0.36 0.17 0.51
Accrued Expenses		 0.15 0.27 0.45 0.76 0.80 0.88 1.43 1.67 1.03 2.23 2.61
Other Current Liabilities		 - - - 3.38 3.75 0.19 0.28 0.28 2.40 0.07 0.30
Total Noncurrent Liabilities		 0.42 0.39 0.03 0.00 0.76 0.63 0.40 0.18 0.04 0.04 0.57
Other Noncurrent Operating Liabilities		 0.00 0.31 0.03 0.00 0.76 0.63 0.40 0.18 0.04 0.04 0.57
Total Equity & Noncontrolling Interests		 -0.06 1.70 9.96 1.33 32 24 14 7.29 4.50 3.53 78
Total Preferred & Common Equity		 -0.06 1.70 9.96 1.33 32 24 14 7.29 4.50 3.53 78
Total Common Equity		 -0.15 1.70 9.96 1.33 32 24 14 7.29 4.50 3.53 78
Common Stock		 3.22 15 31 33 70 69 70 76 84 94 182
Retained Earnings		 -3.37 -13 -21 -28 -35 -44 -56 -69 -80 -91 -104

Quarterly Balance Sheets for Microbot Medical

This table presents Microbot Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 7.37 7.43 5.21 31 33 82 78
Total Current Assets		 7.00 7.14 5.00 31 33 81 77
Cash & Equivalents		 1.16 2.47 0.48 3.22 4.08 6.70 3.66
Restricted Cash		 0.05 0.05 0.05 0.05 0.05 0.05 0.20
Short-Term Investments		 5.19 4.00 3.86 27 29 73 69
Accounts Receivable		 - - - - - - 0.11
Inventories, net		 - - - - - - 2.26
Prepaid Expenses		 0.60 0.63 0.61 0.22 0.16 0.57 0.66
Other Current Assets		 0.00 0.00 0.00 - - - 0.81
Plant, Property, & Equipment, net		 0.13 0.12 0.10 0.08 0.08 0.08 0.19
Total Noncurrent Assets		 0.24 0.17 0.11 0.16 0.17 0.90 1.35
Other Noncurrent Operating Assets		 0.24 0.17 0.11 0.16 0.17 0.90 1.29
Other Noncurrent Nonoperating Assets		 - - - - - - 0.06
Total Liabilities & Shareholders' Equity		 7.37 7.43 5.21 31 33 82 78
Total Liabilities		 1.20 1.38 1.40 1.94 2.77 3.54 3.96
Total Current Liabilities		 1.18 1.34 1.37 1.89 2.73 2.93 3.39
Accounts Payable		 0.10 0.18 0.25 0.19 0.50 0.51 1.09
Accrued Expenses		 0.90 1.05 1.06 1.62 2.12 2.13 1.98
Other Current Liabilities		 0.19 0.11 0.07 0.09 0.10 0.30 0.32
Total Noncurrent Liabilities		 0.02 0.04 0.03 0.05 0.05 0.60 0.57
Other Noncurrent Operating Liabilities		 0.02 0.04 0.03 0.05 0.05 0.60 0.57
Total Equity & Noncontrolling Interests		 6.17 6.06 3.81 29 30 78 74
Total Preferred & Common Equity		 6.17 6.06 3.81 29 30 78 74
Total Common Equity		 6.17 6.06 3.81 29 30 78 74
Common Stock		 88 90 91 122 127 179 182
Retained Earnings		 -82 -84 -88 -94 -97 -101 -108

Annual Metrics And Ratios for Microbot Medical

This table displays calculated financial ratios and metrics derived from Microbot Medical's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 108,807,706.00 16,259,598.00 38,605,333.00 2,975,676.00 4,307,666.00 7,108,133.00 7,108,133.00 7,890,628.00 11,707,317.00 16,932,341.00 67,158,044.00
DEI Adjusted Shares Outstanding		 67,165.00 120,441.00 2,573,689.00 2,975,676.00 4,307,666.00 7,108,133.00 7,108,133.00 7,890,628.00 11,707,317.00 16,932,341.00 67,158,044.00
DEI Earnings Per Adjusted Shares Outstanding		 -13.71 80.23 -1.14 -2.44 -1.68 -1.29 -1.59 -1.67 -0.92 -0.68 -0.20
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -54.75% 126.87% -45.17% -235.97% 1.81% -27.78% -25.05% -16.87% 17.63% -6.21% -24.67%
EBIT Growth		 78.58% 126.83% -45.33% -237.54% 1.38% -27.23% -24.95% -16.99% 17.46% -6.01% -24.10%
NOPAT Growth		 147.90% 137.48% -61.73% -237.54% 0.06% -25.54% -24.95% -16.94% 25.80% -17.96% -26.82%
Net Income Growth		 102.78% 73.46% 69.52% -146.52% 0.18% -26.52% -23.38% -16.40% 18.44% -6.55% -14.85%
EPS Growth		 102.78% 205.26% 69.52% 12.68% 29.46% 24.12% 0.00% 0.00% 41.99% 30.48% 60.27%
Operating Cash Flow Growth		 97.20% -2.75% -517.81% -9.35% -21.49% -12.42% -28.99% -23.47% 26.11% -3.45% -47.80%
Free Cash Flow Firm Growth		 -645.65% 133.65% -63.97% -141.33% -228.74% -105.44% 28.59% -32.45% 37.34% -35.70% -38.71%
Invested Capital Growth		 97.98% -432.93% 19.91% -1,023.71% -4.50% 89.68% -182.55% 17.36% -95.25% -2.90% 44.75%
Revenue Q/Q Growth		 100.00% -100.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 122.82% 145.46% -80.05% -284.74% 3.12% -7.95% -12.99% 6.18% -1.01% -13.49% -2.92%
EBIT Q/Q Growth		 116.99% 147.23% -80.11% -288.79% 2.62% -7.56% -13.04% 6.11% -1.02% -13.27% -2.79%
NOPAT Q/Q Growth		 114.61% 147.34% -86.08% -288.79% 1.31% -7.56% -13.04% 6.14% 9.21% -13.27% -5.04%
Net Income Q/Q Growth		 102.41% 52.29% 32.63% -249.54% 3.41% -9.13% -12.11% 6.14% -1.47% -2.12% -0.55%
EPS Q/Q Growth		 102.41% 132.00% 32.63% -244.29% 2.30% -9.32% 0.00% 0.00% 0.00% 5.19% 34.09%
Operating Cash Flow Q/Q Growth		 97.46% -103.54% -36.18% -2.43% -8.13% 0.68% -12.20% 3.54% 7.00% 1.45% -18.83%
Free Cash Flow Firm Q/Q Growth		 24.45% 147.98% -85.16% -152.41% -256.69% -3.82% -9.96% 1.70% 29.73% -22.33% -33.22%
Invested Capital Q/Q Growth		 96.93% 80.14% -1,942.11% -2,835.07% -5.44% -216.42% -86.90% -12.88% 0.00% -244.12% 44.72%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% -100.29% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.02% 100.00% 100.00%
Interest Burden Percent		 99.34% 100.00% -55.91% 100.22% 101.44% 100.88% 99.61% 99.11% 97.92% 98.43% 91.09%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 31.31% -906.47% -46.52% -123.11% -44.09% -32.84% -58.48% -121.53% -182.19% -284.97% -32.42%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 30.84% -656.90% -42.85% -117.89% -44.09% -32.84% -58.48% -121.53% -182.19% -284.97% -32.42%
Return on Equity Simple (ROE_SIMPLE)		 -1,420.31% -569.75% -29.56% -545.86% -22.98% -37.72% -78.67% -180.66% -238.61% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 0.92 9.64 3.69 -5.07 -5.07 -6.36 -7.95 -9.30 -6.90 -8.14 -10
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -0.12% -1,455.90% -98.64% -27.23% -10.65% -9.30% -16.69% -32.45% -52.22% -55.31% -6.71%
Return On Investment Capital (ROIC_SIMPLE)		 257.75% - - - - - - - -153.27% -230.52% -13.31%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 0.92 9.64 5.27 -7.24 -7.14 -9.09 -11 -13 -11 -12 -14
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.93 9.65 5.29 -7.19 -7.06 -9.02 -11 -13 -11 -12 -14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 6.50 3.95 3.85 1.39 2.01 3.71 3.26 4.27 5.37 1.73
Price to Tangible Book Value (P/TBV)		 0.00 6.50 3.95 3.85 1.39 2.01 3.71 3.26 4.27 5.37 1.73
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 1.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 87.68% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 48.70 0.92 5.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 49.60 0.92 5.52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 49.60 0.92 7.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.89 8.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 -6.55 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 -6.55 0.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.71 -1.24 -1.06 -1.36 -1.24 -1.08 -1.04 -1.10 -1.25 -1.49 -1.04
Leverage Ratio		 5.68 1.83 1.14 1.45 1.31 1.14 1.11 1.21 1.52 1.79 1.08
Compound Leverage Factor		 5.64 1.83 -0.64 1.45 1.33 1.15 1.11 1.20 1.48 1.76 0.98
Debt to Total Capital		 118.03% 3.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 118.03% 3.35% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 24.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 22.01% 4.78% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -42.54% 74.65% 95.22% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.45 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -0.02 -0.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.45 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.46 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -0.02 -0.27 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.46 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 62.40 10.57 42.58 -9.47 3.75 12.50 7.52 -7.50 -14.11 -22.25 18.95
Noncontrolling Interest Sharing Ratio		 1.50% 27.53% 7.90% 4.24% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.82 4.23 20.70 1.23 7.45 18.78 8.00 4.26 2.09 2.37 23.33
Quick Ratio		 2.82 3.46 20.43 1.10 6.48 18.33 7.81 3.96 1.69 2.22 22.97
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -3.07 9.99 3.60 -1.49 -4.89 -10 -7.18 -9.50 -5.96 -8.08 -11
Operating Cash Flow to CapEx		 -38,250.00% -3,144.00% -8,372.41% -2,381.17% 0.00% -7,969.23% -13,556.52% -13,748.81% -25,857.58% -35,308.00% -21,743.33%
Free Cash Flow to Firm to Interest Expense		 -511.87 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 -127.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 -127.83 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -0.08 -0.44 -0.35 -3.93 -4.11 -0.42 -1.20 -0.99 -1.93 -1.99 -1.10
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 3.99 -0.36 0.09 -3.58 -0.18 3.69 -0.77 0.21 -0.94 -0.06 0.89
Enterprise Value (EV)		 45 8.89 29 -0.14 8.16 24 38 15 13 13 56
Market Capitalization		 45 11 39 5.12 44 49 53 24 19 19 134
Book Value per Share		 $0.00 $0.10 $0.26 $0.45 $7.32 $3.42 $2.02 $0.92 $0.38 $0.21 $1.15
Tangible Book Value per Share		 $0.00 $0.10 $0.26 $0.45 $7.32 $3.42 $2.02 $0.92 $0.38 $0.21 $1.15
Total Capital		 0.36 2.27 10 1.33 32 24 14 7.29 4.50 3.53 78
Total Debt		 0.42 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.42 0.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -0.02 -2.63 -11 -5.26 -36 -25 -16 -8.28 -6.43 -5.52 -79
Capital Expenditures (CapEx)		 0.00 0.03 0.06 0.22 -0.04 0.09 0.07 0.08 0.03 0.03 0.06
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -0.12 -0.18 -0.41 -4.19 -4.54 -0.82 -1.68 -1.53 -2.30 -2.16 -2.19
Debt-free Net Working Capital (DFNWC)		 0.32 2.53 10 1.07 31 24 14 6.75 4.14 3.36 76
Net Working Capital (NWC)		 0.32 2.53 10 1.07 31 24 14 6.75 4.14 3.36 76
Net Nonoperating Expense (NNE)		 0.01 19 6.63 2.19 2.18 2.81 3.36 3.87 3.84 3.31 2.82
Net Nonoperating Obligations (NNO)		 -0.02 -2.63 -11 -5.26 -36 -25 -16 -8.28 -6.43 -5.52 -79
Total Depreciation and Amortization (D&A)		 0.02 0.01 0.02 0.05 0.08 0.07 0.08 0.10 0.11 0.09 0.05
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($615.60) $6.00 $2.70 ($2.41) ($1.70) ($1.29) ($1.59) ($1.81) ($1.05) ($0.73) ($0.29)
Adjusted Weighted Average Basic Shares Outstanding		 69.45K 952.92K 2.81M 4.31M 4.27M 7.11M 7.11M 7.26M 10.20M 15.64M 45.79M
Adjusted Diluted Earnings per Share		 ($615.60) $6.00 $2.70 ($2.41) ($1.70) ($1.29) ($1.59) $0.00 ($1.05) ($0.73) ($0.29)
Adjusted Weighted Average Diluted Shares Outstanding		 69.45K 952.92K 2.81M 4.31M 4.27M 7.11M 7.11M 8.13M 10.20M 15.64M 45.79M
Adjusted Basic & Diluted Earnings per Share		 ($615.60) $6.00 $2.70 ($2.41) ($1.70) ($1.29) ($1.59) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 59.14K 952.92K 2.18M 2.90M 4.27M 7.12M 7.11M 8.13M 14.40M 34.74M 67.16M
Normalized Net Operating Profit after Tax (NOPAT)		 0.64 6.74 3.69 -5.07 -5.07 -6.36 -7.95 -9.30 -6.90 -8.14 -10
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 152.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 152.50 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 152.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 152.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Microbot Medical

This table displays calculated financial ratios and metrics derived from Microbot Medical's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 11,707,317.00 11,707,317.00 14,398,964.00 14,398,964.00 16,504,433.00 16,932,341.00 34,744,476.00 36,377,812.00 45,545,939.00 67,158,044.00 67,158,044.00
DEI Adjusted Shares Outstanding		 11,707,317.00 11,707,317.00 14,398,964.00 14,398,964.00 16,504,433.00 16,932,341.00 34,744,476.00 36,377,812.00 45,545,939.00 67,158,044.00 67,158,044.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.21 -0.27 -0.16 -0.17 -0.19 -0.20 -0.07 -0.10 -0.08 -0.05 -0.05
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 26.82% 33.01% 18.59% -8.66% -29.83% -67.44% -14.18% -48.62% -17.52% -21.27% -60.15%
EBIT Growth		 26.77% 32.59% 18.33% -8.05% -29.72% -65.86% -13.46% -48.27% -17.00% -20.64% -59.70%
NOPAT Growth		 26.77% 32.59% 18.33% -8.05% -29.72% -65.86% -26.72% -48.27% -17.00% -20.64% -43.00%
Net Income Growth		 29.47% -5.20% 16.89% -7.78% -31.44% -7.55% -9.70% -41.99% -11.26% -2.12% -41.14%
EPS Growth		 0.00% 0.00% 52.78% 32.00% 4.76% 17.39% 52.94% 41.18% 65.00% 78.95% 37.50%
Operating Cash Flow Growth		 43.99% 26.07% 24.45% -5.56% -66.71% 7.14% -18.76% -31.48% -39.22% -122.24% -75.82%
Free Cash Flow Firm Growth		 -21.04% 78.58% 37.60% 7.83% 34.83% -364.72% 49.45% 61.66% 25.36% -61.48% -582.76%
Invested Capital Growth		 0.00% -95.25% 10.85% 9.00% 0.00% -2.90% -546.52% -420.88% -243.94% 44.75% 190.45%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -9.83% 19.45% -15.89% -5.98% -31.24% -3.88% 20.98% -37.96% -3.77% -7.19% -4.36%
EBIT Q/Q Growth		 -9.47% 18.71% -15.28% -5.33% -31.42% -3.94% 21.14% -37.63% -3.71% -7.17% -4.40%
NOPAT Q/Q Growth		 -9.47% 18.71% -15.28% -5.33% -31.42% -3.94% 11.92% -23.24% -3.71% -7.17% -4.40%
Net Income Q/Q Growth		 -6.95% -28.95% 24.83% -3.96% -30.43% -5.51% 23.32% -34.56% -2.20% 3.16% -5.98%
EPS Q/Q Growth		 16.00% -9.52% 26.09% 0.00% -17.65% 5.00% 57.89% -25.00% 30.00% 42.86% -25.00%
Operating Cash Flow Q/Q Growth		 10.73% -10.03% -32.89% 19.13% -40.98% 38.71% -69.96% 10.47% -49.28% 2.16% -34.46%
Free Cash Flow Firm Q/Q Growth		 -35.89% 81.01% -236.27% -6.24% 3.92% -35.39% 63.42% 19.42% -87.05% -192.92% -54.65%
Invested Capital Q/Q Growth		 100.00% 0.00% 88.10% -97.83% -27.03% -244.12% 25.24% -59.38% 16.12% 44.72% 222.38%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.90%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,102.86%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,114.29%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -4,114.29%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,496.19%
Tax Burden Percent		 100.00% 100.06% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 96.15% 152.42% 99.45% 98.17% 97.42% 98.89% 96.16% 94.01% 92.64% 83.71% 84.98%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -182.19% -186.26% -134.46% -294.25% -284.97% -66.48% -69.80% -31.87% -32.42% -27.58%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,045.46%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -7.93%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -6.74%
Return on Common Equity (ROCE)		 0.00% -182.19% -186.26% -134.46% -294.25% -284.97% -66.48% -69.80% -31.87% -32.42% -27.58%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -166.34% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -1.78 -1.45 -1.67 -1.76 -2.31 -2.40 -2.11 -2.61 -2.70 -2.90 -3.02
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,880.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -23.20% -12.21% -8.58% -41.27% -16.58% -2.64% -4.56% -2.07% -1.35% -1.25%
Return On Investment Capital (ROIC_SIMPLE)		 - -32.16% -27.06% -29.03% -60.66% -68.02% -7.30% -8.58% -3.46% -3.73% -4.08%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 98.10%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,884.76%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,231.43%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 4,116.19%
Earnings before Interest and Taxes (EBIT)		 -2.54 -2.07 -2.38 -2.51 -3.30 -3.43 -2.71 -3.72 -3.86 -4.14 -4.32
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.52 -2.03 -2.36 -2.50 -3.28 -3.40 -2.69 -3.71 -3.85 -4.13 -4.31
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 4.27 2.87 2.43 3.87 5.37 1.81 3.02 1.78 1.73 2.18
Price to Tangible Book Value (P/TBV)		 0.00 4.27 2.87 2.43 3.87 5.37 1.81 3.02 1.78 1.73 2.18
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1,541.44
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 66.28
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 849.06
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 0.00 -1.25 -1.04 -1.06 -1.15 -1.49 -1.05 -1.08 -1.03 -1.04 -1.00
Leverage Ratio		 0.00 1.52 1.23 1.18 1.37 1.79 1.09 1.11 1.06 1.08 1.06
Compound Leverage Factor		 0.00 2.31 1.23 1.16 1.33 1.77 1.05 1.05 0.98 0.90 0.90
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 -10.58 -6.82 -9.67 -18.47 -17.77 12.81 16.45 22.84 19.37 23.53
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 2.09 5.92 5.32 3.64 2.37 16.19 12.06 27.53 23.33 22.59
Quick Ratio		 0.00 1.69 5.37 4.82 3.16 2.22 16.05 11.98 27.32 22.97 21.44
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2.66 -0.50 -1.70 -1.80 -1.73 -2.35 -0.86 -0.69 -1.29 -3.79 -5.86
Operating Cash Flow to CapEx		 -5,910.71% 0.00% -17,285.71% -48,925.00% 0.00% -24,157.14% -22,107.69% -28,588.89% -29,546.15% -15,032.00% -4,678.70%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.79
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.16
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2,252.01
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -2,252.01
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -1.93 -0.23 -0.46 -0.58 -1.99 -1.49 -2.37 -1.99 -1.10 1.35
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.48
Increase / (Decrease) in Invested Capital		 0.88 -0.94 0.03 0.05 -0.58 -0.06 -1.26 -1.92 -1.41 0.89 2.83
Enterprise Value (EV)		 0.00 13 11 8.18 10 13 22 59 59 56 89
Market Capitalization		 16 19 18 15 15 19 52 92 139 134 162
Book Value per Share		 $0.00 $0.38 $0.43 $0.42 $0.23 $0.21 $0.83 $0.83 $1.72 $1.15 $1.10
Tangible Book Value per Share		 $0.00 $0.38 $0.43 $0.42 $0.23 $0.21 $0.83 $0.83 $1.72 $1.15 $1.10
Total Capital		 0.00 4.50 6.17 6.06 3.81 3.53 29 30 78 78 74
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 0.00 -6.43 -6.40 -6.51 -4.39 -5.52 -30 -33 -80 -79 -73
Capital Expenditures (CapEx)		 0.03 -0.01 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.03 0.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -2.30 -0.58 -0.71 -0.76 -2.16 -1.68 -2.56 -2.36 -2.19 0.44
Debt-free Net Working Capital (DFNWC)		 0.00 4.14 5.82 5.80 3.62 3.36 29 30 78 76 73
Net Working Capital (NWC)		 0.00 4.14 5.82 5.80 3.62 3.36 29 30 78 76 73
Net Nonoperating Expense (NNE)		 0.67 1.71 0.70 0.71 0.91 0.99 0.49 0.89 0.87 0.57 0.65
Net Nonoperating Obligations (NNO)		 0.00 -6.43 -6.40 -6.51 -4.39 -5.52 -30 -33 -80 -79 -73
Total Depreciation and Amortization (D&A)		 0.02 0.04 0.03 0.01 0.02 0.03 0.02 0.01 0.01 0.01 0.01
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 420.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 69,658.10%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 69,658.10%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($0.23) ($0.17) ($0.17) ($0.20) ($0.19) ($0.08) ($0.10) ($0.07) ($0.04) ($0.05)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 10.20M 14.06M 14.85M 16.47M 15.64M 31.09M 36.49M 48.10M 45.79M 67.16M
Adjusted Diluted Earnings per Share		 $0.00 ($0.23) ($0.17) ($0.17) ($0.20) ($0.19) ($0.08) ($0.10) ($0.07) ($0.04) ($0.05)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 10.20M 14.06M 14.85M 16.47M 15.64M 31.09M 36.49M 48.10M 45.79M 67.16M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 14.40M 14.40M 16.50M 16.93M 34.74M 36.38M 45.55M 67.16M 67.16M 67.16M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.78 -1.45 -1.67 -1.76 -2.31 -2.40 -2.11 -2.61 -2.70 -2.90 -3.02
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,880.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -3,496.19%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Microbot Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Microbot Medical's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Microbot Medical's net income appears to be on an upward trend, with a most recent value of -$13.14 million in 2025, falling from $909 thousand in 2015. The previous period was -$11.44 million in 2024. Check out Microbot Medical's forecast to explore projected trends and price targets.

Microbot Medical's total operating income in 2025 was -$14.74 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $14.74 million

Over the last 10 years, Microbot Medical's total revenue changed from $0.00 in 2015 to $0.00 in 2025, a change of 0.0%.

Microbot Medical's total liabilities were at $3.99 million at the end of 2025, a 59.5% increase from 2024, and a 852.3% increase since 2015.

In the past 10 years, Microbot Medical's cash and equivalents has ranged from $437 thousand in 2015 to $28.77 million in 2019, and is currently $3.91 million as of their latest financial filing in 2025.

Over the last 10 years, Microbot Medical's book value per share changed from 0.00 in 2015 to 1.15 in 2025, a change of -82,585.7%.


Related Companies

Financial statements for NASDAQ:MBOT last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Move your money (NOT into the next AI IPO)
While headlines focus on AI IPOs, the world's largest investors are moving capital into one asset at the faste...
Stansberry Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Ray Dalio: Buy Gold. Get Paid.
Ray Dalio, founder of Bridgewater Associates, is urging investors to hold 15% of their portfolio in gold and c...
Investors Alley | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Simple Options Trading For Beginners' book at no cost - normally $29.97. It ou...
Profits Run | Sponsoredtc pixel
Executive order could send gold to 6,000 per ounce
Executive Order 14330 will allow Americans to hold precious metals inside 401(k)s for the first time ever - an...
Cedar Gold Group | Sponsoredtc pixel